Science

Zantrene® (bisantrene dihydrochloride) is a small molecule anti-cancer drug which has clinical and preclinical efficacy as both a low dose, highly targeted precision oncology agent and cardio-protective chemotherapeutic. The recent identification that Zantrane® is an highly potent FTO inhibitor has driven intense scientific and clinical interest in Zantrene as a rapidly translatable pharmaceutical agent able to target the exciting m6A RNA methylation pathway. https://youtu.be/BiM2feiwPs0 History of Zantrene Zantrene® was originally developed by Lederle Laboratories in the 1970s as a lower cardiotoxic alternative to the commonly used anthracycline chemotherapeutics. Lederle trialled Zantrene…

Latest News

+

Phase 1b dose escalation stage of the Phase 1b/2 Zantrene study in AML has completed using a 4-day treatment of…

Race Oncology Limited (“Race”) is pleased to announce it has received Research Governance Office (RGO) approval from the Calvary Mater…

March-2022-Quarterly-Activity-Report-and-Appendix-4CDownload